000294684 001__ 294684
000294684 005__ 20241127182726.0
000294684 0247_ $$2doi$$a10.1093/noajnl/vdae155
000294684 0247_ $$2pmid$$apmid:39582811
000294684 0247_ $$2pmc$$apmc:PMC11582646
000294684 0247_ $$2ISSN$$a2632-2498
000294684 037__ $$aDKFZ-2024-02419
000294684 041__ $$aEnglish
000294684 082__ $$a610
000294684 1001_ $$00000-0001-7281-6306$$aBaugh, Joshua N$$b0
000294684 245__ $$aTreatment-related survival patterns in diffuse intrinsic pontine glioma using a historical cohort: A report from the European Society for Pediatric Oncology DIPG/DMG Registry.
000294684 260__ $$aOxford$$bOxford University Press$$c2024
000294684 3367_ $$2DRIVER$$aarticle
000294684 3367_ $$2DataCite$$aOutput Types/Journal article
000294684 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1732692656_23889
000294684 3367_ $$2BibTeX$$aARTICLE
000294684 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000294684 3367_ $$00$$2EndNote$$aJournal Article
000294684 520__ $$aOur aim is to investigate the association of treatment with survival in patients with diffuse intrinsic pontine glioma (DIPG) by examining 6 historical treatment paths.We retrospectively analyzed data from 409 patients with radiologically centrally reviewed DIPG, sourced from the German Society of Pediatric Oncology and Hematology HIT-HGG trial database and the SIOPE-DIPG/DMG Registry. Survival outcomes were estimated using the Kaplan-Meier method, and univariable and multivariable Cox proportional hazard models were estimated to study treatment effects.The median overall survival (OS) from diagnosis was 11.2 months (95% confidence interval [CI], 10.5-11.9). Patients who by choice received no frontline treatment had an OS of 3.0 months (95% CI, 2.0-4.0), while those treated with radiation therapy (RT) alone had a median OS of 10.4 months (95% CI, 9.1-11.8). Those receiving RT combined with chemotherapy had the longest median OS of 11.7 months (95% CI, 10.8-12.6). The median post-progression survival (PPS) was 4.1 months (95% CI, 3.5-4.7). Patients who relapsed and did not receive treatment had a PPS of 2.2 months (95% CI, 1.8-2.6), while those treated with chemotherapy alone had a PPS of 4.4 months (95% CI, 3.7-5.0), and those who underwent reirradiation, with or without chemotherapy, had the longest survival after relapse of 6.6 months (95% CI, 5.3-8.0). Treatment differences remained significant in multivariable analysis adjusted for age and symptom duration in both diagnosis and relapse setting.This study shows increased survival outcomes associated with radiation and chemotherapy treatment or a combination thereof, at diagnosis and relapse, in a historical DIPG cohort.
000294684 536__ $$0G:(DE-HGF)POF4-312$$a312 - Funktionelle und strukturelle Genomforschung (POF4-312)$$cPOF4-312$$fPOF IV$$x0
000294684 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000294684 650_7 $$2Other$$aDIPG
000294684 650_7 $$2Other$$adiffuse intrinsic pontine glioma
000294684 650_7 $$2Other$$adiffuse midline glioma
000294684 650_7 $$2Other$$ahistorical control
000294684 650_7 $$2Other$$aregistry
000294684 7001_ $$aVeldhuijzen van Zanten, Sophie$$b1
000294684 7001_ $$aFiocco, Marta$$b2
000294684 7001_ $$aColditz, Niclas$$b3
000294684 7001_ $$aHoffmann, Marion$$b4
000294684 7001_ $$aJanssens, Geert O$$b5
000294684 7001_ $$aValentini, Chiara$$b6
000294684 7001_ $$aHargrave, Darren$$b7
000294684 7001_ $$aWiese, Maria$$b8
000294684 7001_ $$avon Bueren, André O$$b9
000294684 7001_ $$aKarremann, Michael$$b10
000294684 7001_ $$aPerwein, Thomas$$b11
000294684 7001_ $$aNussbaumer, Gunther$$b12
000294684 7001_ $$aBenesch, Martin$$b13
000294684 7001_ $$0P:(DE-He78)a46a5b2a871859c8e2d63d2f8c666807$$aSturm, Dominik$$b14$$udkfz
000294684 7001_ $$aGielen, Gerrit H$$b15
000294684 7001_ $$0P:(DE-He78)4be9ccb23f3e472b97743845cd2b3fe9$$aKrause, Mechthild$$b16$$udkfz
000294684 7001_ $$aEyrich, Matthias$$b17
000294684 7001_ $$aHoving, Eelco W$$b18
000294684 7001_ $$aBison, Brigitte$$b19
000294684 7001_ $$avan Vuurden, Dannis G$$b20
000294684 7001_ $$aKramm, Christof M$$b21
000294684 773__ $$0PERI:(DE-600)3009682-0$$a10.1093/noajnl/vdae155$$gVol. 6, no. 1, p. vdae155$$n1$$pvdae155$$tNeuro-oncology advances$$v6$$x2632-2498$$y2024
000294684 909CO $$ooai:inrepo02.dkfz.de:294684$$pVDB
000294684 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)a46a5b2a871859c8e2d63d2f8c666807$$aDeutsches Krebsforschungszentrum$$b14$$kDKFZ
000294684 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)4be9ccb23f3e472b97743845cd2b3fe9$$aDeutsches Krebsforschungszentrum$$b16$$kDKFZ
000294684 9131_ $$0G:(DE-HGF)POF4-312$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vFunktionelle und strukturelle Genomforschung$$x0
000294684 9141_ $$y2024
000294684 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bNEURO-ONCOL ADV : 2022$$d2023-10-27
000294684 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-10-27
000294684 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-10-27
000294684 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central$$d2023-10-27
000294684 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2022-11-23T11:49:35Z
000294684 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2022-11-23T11:49:35Z
000294684 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Anonymous peer review$$d2022-11-23T11:49:35Z
000294684 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-10-27
000294684 915__ $$0StatID:(DE-HGF)0112$$2StatID$$aWoS$$bEmerging Sources Citation Index$$d2023-10-27
000294684 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-10-27
000294684 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2023-10-27
000294684 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2023-10-27
000294684 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2023-10-27
000294684 9201_ $$0I:(DE-He78)B360-20160331$$kB360$$lPädiatrische Gliomforschung$$x0
000294684 9201_ $$0I:(DE-He78)HD01-20160331$$kHD01$$lDKTK HD zentral$$x1
000294684 9201_ $$0I:(DE-He78)DD01-20160331$$kDD01$$lDKTK Koordinierungsstelle Dresden$$x2
000294684 980__ $$ajournal
000294684 980__ $$aVDB
000294684 980__ $$aI:(DE-He78)B360-20160331
000294684 980__ $$aI:(DE-He78)HD01-20160331
000294684 980__ $$aI:(DE-He78)DD01-20160331
000294684 980__ $$aUNRESTRICTED